BMS-986207 for Non-Small Cell Lung Cancer

$Form.Name, Milwaukee, WI
BMS-986207 +3 morePhase 2Waitlist AvailableResearch Sponsored by Bristol-Myers Squibb

Study Summary

This trial will test a new cancer treatment involving a combination of drugs. The goal is to see if it is safe and effective for people with stage IV non-small cell lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)
Secondary outcome measures
DOR based on RECIST v1.1 by Investigator's assessment
Duration of Response (DOR) based on RECIST v1.1 by BICR
Incidence of AEs leading to discontinuation
+11 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment3 Interventions
Group II: Arm AExperimental Treatment3 Interventions
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Find a site

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,562 Previous Clinical Trials
4,030,045 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the BMS-986207 research landscape?

"BMS-986207 was first studied a decade ago, in 2009, at Texas Children's Hospital. To date, there have been 18638 completed trials worldwide. Currently, 796 clinical trials are still running; many of which are based in Orange City, Kentucky."

Answered by AI

Which patients does BMS-986207 help the most?

"BMS-986207 has shown to be effective in the treatment of malignant neoplasms, unresectable melanoma, and previous anti-angiogenic therapy."

Answered by AI

Are volunteers still being accepted for this experiment?

"Yes, this is an ongoing study that is currently seeking patients. The trial was first posted on October 3rd, 2020 and has since been updated November 15th, 2020. A total of 180 individuals are needed to be recruited from 19 different locations."

Answered by AI

How many people are part of this clinical trial?

"That is correct, the information available on clinicaltrials.gov suggests that this trial is seeking new participants. The first posting was on October 3rd, 2020 and there have been edits made as recently as November 15th, 2020. In total, the study needs to enrol 180 patients from 19 different sites."

Answered by AI

Are there any risks associated with taking BMS-986207?

"BMS-986207 is still being tested for efficacy in Phase 2 trials, but there is some data supporting its safety which landed it a score of 2."

Answered by AI

In how many different places is this clinical trial being performed?

"This clinical trial has 20 locations, with the primary operating centres being Saint Alphonsus Regional Medical Center in Orange City, Kentucky, Mid Florida Hematology and Oncology Center in Edgewood, Idaho, and Compassionate Cancer Care Medical Group in Boise, New York."

Answered by AI
~1 spots leftby Sep 2024